Literature DB >> 8280931

Identification and characterization of Helicobacter pylori phospholipase C activity.

J H Weitkamp1, G I Pérez-Pérez, G Bode, P Malfertheiner, M J Blaser.   

Abstract

We analyzed 11 H. pylori isolates from humans using the artificial chromogenic substrate paranitrophenylphosphorylcholine to detect phospholipase C (PLC) activity. The range of PLC in sonicates was 8.8-92.3 (Mean 56.9 +/- 6.5) nmol of substrate hydrolysed min-1 mg-1 protein; the amount of activity was not associated with urease or cytotoxin levels. Addition of sorbitol or glycerol enhanced PLC activity of H. pylori sonicate and purified PLC from C. perfringens (PLC1) but not purified PLC from B. cereus (PLC3). H. pylori sonicates had little acid phosphatase and no detectable alkaline phosphatase activity, and H. pylori PLC showed markedly different biochemical characteristics from either phosphatase. In total, these studies indicate that activity measured in H. pylori sonicate by PLC assay is due to PLC and not phosphatase activity. The temperature optimum for PLC activity of H. pylori sonicate was 56 degrees C and for PLC 1 was 65 degrees C. For H. pylori PLC and PLC1, optimal activity occurred at pH 8. Despite multiple similarities between H. pylori PLC and PLC1, known PLC inhibitors show different interactions with each enzyme. Although PLC activity is present in many subcellular constituents of H. pylori, including culture supernatants and water extracts, highest specific activity is associated with a membrane-enriched fraction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280931     DOI: 10.1016/s0934-8840(11)80937-0

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  7 in total

1.  Role of vacA and cagA in Helicobacter pylori inhibition of mucin synthesis in gastric mucous cells.

Authors:  W Beil; M L Enss; S Müller; B Obst; K F Sewing; S Wagner
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 2.  Immunopathology of Helicobacter pylori infection and disease.

Authors:  S J Czinn; J G Nedrud
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.

Authors:  W Stremmel; U Merle; A Zahn; F Autschbach; U Hinz; R Ehehalt
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 4.  Metabolism and genetics of Helicobacter pylori: the genome era.

Authors:  A Marais; G L Mendz; S L Hazell; F Mégraud
Journal:  Microbiol Mol Biol Rev       Date:  1999-09       Impact factor: 11.056

5.  Helicobacter pylori EstV: identification, cloning, and characterization of the first lipase isolated from an epsilon-proteobacterium.

Authors:  Cristian Ruiz; Serena Falcocchio; F I Javier Pastor; Luciano Saso; Pilar Diaz
Journal:  Appl Environ Microbiol       Date:  2007-02-09       Impact factor: 4.792

Review 6.  Helicobacter pylori.

Authors:  B E Dunn; H Cohen; M J Blaser
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

7.  Mutation of the cytotoxin-associated cagA gene does not affect the vacuolating cytotoxin activity of Helicobacter pylori.

Authors:  M K Tummuru; T L Cover; M J Blaser
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.